Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification

Podobne knjige/članki

• Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
  od: Yoshimura, Katsuhiro, et al.
  Izdano: (2017)
• Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation
  od: Yao, Jing-hao, et al.
  Izdano: (2019)
• Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
  od: Wang, Wenxian, et al.
  Izdano: (2019)
• Emergence of Concurrent Multiple EGFR Mutations and MET Amplification in a Patient With EGFR-Amplified Advanced Gastric Cancer Treated With Cetuximab
  od: Nakamura, Yoshiaki, et al.
  Izdano: (2020)
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
  od: Bean, James, et al.
  Izdano: (2007)